OSTX appoints Frank Knuettel II as CFO, Kerry Clem as Chief Commercial Officer

OS Therapies announced the effective September 29, 2026 appointment of Frank Knuettel II as CFO (replacing Christopher P. Acevedo, who will consult) and Kerry Clem as Chief Commercial Officer. Knuettel brings three decades of experience in life sciences and technology, including prior roles as CEO/CFO at Channel Therapeutics and Pelthos, and has experience with M&A and capital raises. While a CFO change can signal strategic shifts, the filing does not disclose any sudden departure or crisis—Acevedo transitions to consulting—making this a routine executive appointment rather than a material eve

OS Therapies replaced its CFO with Frank Knuettel, an experienced executive from biotech companies. The old CFO will stay as a consultant. This is a planned management change, not a crisis exit.